Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
(Corrects to clarify the total number of patients in the study in paragraph 10) May 27 (Reuters) - The U.S. Food and Drug ...
GlobalData on MSN
FDA grants priority review for Sanofi’s venglustat NDA
The decision is anticipated by 25 November 2026.
Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. The new target action date is November 17.
Replimune (REPL) shares climbed more than 60% in the premarket on Friday after the company announced plans to resubmit a marketing application for its lead asset RP1 in the U.S., following its second ...
Stocktwits on MSN
ABBV stock gains on winning FDA approval for rare blood cancer drug
The drug is specifically approved to treat blastic plasmacytoid dendritic cell neoplasm (an ultra-rare and aggressive type of ...
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin ...
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat ...
The Food and Drug Administration is a government agency that regulates certain food, drugs, cosmetics, and medical products.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results